Replies to post #185896 on Biotech Values

[DewDiligence]

Re: Gene therapy

I have AGTC in the 2015 SI charity contest (but not in my real portfolios). The highest-profile GT names such as BLUE and AAVL have become unduly expensive on a risk-adjusted basis, IMO.